InsiderTrades

Form 4 for NXDT NEXPOINT DIVERSIFIED REAL ESTATE TRUST

Accepted 2025-02-03 00:00:00 ET · period of report 2025-01-31 · accession 0001437749-25-002605 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
MI 2025-02-03 2025-01-31 NXDT DONDERO JAMES D See Remarks, Dir, 10% A - Grant — +257.6K 1.63M +19% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-01-31 A A 90,327.16 — 1,461,495.14 I See Footnote — — (F1) Under the terms of the Advisory Agreement, dated July 1, 2022, by and between NexPoint Diversified Real Estate Trust (the "Company") and NexPoint Real Estate Advisers X, L.P. (the "Adviser"), as amended by that First Amendment to Advisory Agreement dated October 25, 2022, as amended by that Second Amendment to Advisory Agreement, dated April 11, 2023 and as amended by that Third Amendment to Advisory Agreement dated July 22, 2024 (the "Advisory Agreement"), the Adviser receives payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the volume-weighted average price ("VWAP") of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 90,327.16 common shares to the Adviser as payment of its fees for the month of October at a VWAP of $5.5431 per share. (F2) 35,935 shares are held by Drugcrafters, L.P. ("Drugcrafters"), 77,705.36 shares are held by PCMG Trading Partners XXIII, L.P., 193,808 shares are held by Governance Re Ltd. and 1,321,272.24 shares (following the transactions described herein) are held by the Adviser. Mr. Dondero owns 75% of PCMG Trading Partners XXIII, L.P. ("PCMG") and PCMG owns 99% of Drugcrafters. Drugcrafters, PCMG, Governance Re Ltd. and the Adviser are ultimately controlled by Mr. Dondero. Mr. Dondero may be deemed to be an indirect beneficial owner of shares held by such entities. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
2 Common Common Stock 2025-01-31 A A 95,314.77 — 1,556,809.91 I See Footnote — — (F3) Under the terms of the Advisory Agreement, the Adviser receives payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the VWAP of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 95,314.77 common shares to the Adviser as payment of its fees for the month of November at a VWAP of $5.3913 per share. (F2) 35,935 shares are held by Drugcrafters, L.P. ("Drugcrafters"), 77,705.36 shares are held by PCMG Trading Partners XXIII, L.P., 193,808 shares are held by Governance Re Ltd. and 1,321,272.24 shares (following the transactions described herein) are held by the Adviser. Mr. Dondero owns 75% of PCMG Trading Partners XXIII, L.P. ("PCMG") and PCMG owns 99% of Drugcrafters. Drugcrafters, PCMG, Governance Re Ltd. and the Adviser are ultimately controlled by Mr. Dondero. Mr. Dondero may be deemed to be an indirect beneficial owner of shares held by such entities. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
3 Common Common Stock 2025-01-31 A A 71,910.68 — 1,628,720.59 I See Footnote — — (F4) Under the terms of the Advisory Agreement, the Adviser receives payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the VWAP of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 71,910.68 common shares to the Adviser as payment of its fees for the month of December at a VWAP of $6.9627 per share. (F5) Includes shares received pursuant to an elective stock dividend paid on the Company's common shares on December 31, 2024. (F2) 35,935 shares are held by Drugcrafters, L.P. ("Drugcrafters"), 77,705.36 shares are held by PCMG Trading Partners XXIII, L.P., 193,808 shares are held by Governance Re Ltd. and 1,321,272.24 shares (following the transactions described herein) are held by the Adviser. Mr. Dondero owns 75% of PCMG Trading Partners XXIII, L.P. ("PCMG") and PCMG owns 99% of Drugcrafters. Drugcrafters, PCMG, Governance Re Ltd. and the Adviser are ultimately controlled by Mr. Dondero. Mr. Dondero may be deemed to be an indirect beneficial owner of shares held by such entities. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.